Compare ARK Genomic Revolution ETF (ARKG) vs Medtronic PLC (MDT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Medtronic PLC — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Medtronic PLC trades at $84.19 (market cap $107.36B). The key difference: Medtronic PLC pays a 3.43% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| ARKG | MDT | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $105.35 |
52-Week Low | $23.09 | $73.75 |
Market Cap | — | $107.36B |
Enterprise Value | — | $126.10B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Medtronic (MDT) trades at $83.87, up 1.8% with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats with Q1 2026 EPS of $1.55 exceeding expectations, while revenue growth accelerated to $33.54B in 2025. Analyst consensus remains strongly positive with 58% buy ratings and a $97.31 price target, representing 16% upside potential from current levels.
MDT presents an attractive investment case with solid profitability metrics, dividend aristocrat status, and accelerating revenue growth. Key risks include increasing debt levels (debt-to-asset ratio rose to 31.11% in 2025) and margin pressure from tariffs. The company's strategic acquisitions and innovation in cardiovascular and neuroscience segments support long-term growth prospects despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
